Biotech Values

[DewDiligence]

AMGN/AGN report positive phase-3 data for Avastin FoB:

http://finance.yahoo.com/news/amgen-allergan-announce-positive-top-130000816.html

The primary endpoint, an assessment of objective response rates (ORR), was within the prespecified margin for ABP 215 compared to bevacizumab, showing clinical equivalence. Safety and immunogenicity of ABP 215 were comparable to bevacizumab. Secondary endpoint results were consistent with the primary finding and included risk difference of ORR, duration of response and progression-free survival (PFS).

AMGN and AGN are also collaborating on FoBs for Rituxan, Herceptin, and Erbitux (#msg-70097496). Although it was previously reported that AMGN and AGN were also collaborating on FoBs for Humira and Remicade (#msg-84340328), AMGN is now developing those programs on its own (#msg-110547164).